US Material Events SEC 8-K Filings — June 29, 2026

29-06-2026

PEDEVCO CORP announced the mutual departure of Paul Pinkston as Chief Accounting Officer, effective June 23, 2026. The filing does not disclose any financial impact or replacement details.

• · Departure was mutual and effective June 23, 2026.
• · No successor or interim CAO was announced.
• · No compensatory arrangements or severance were disclosed.

29-06-2026

Decoy Therapeutics, Inc. announced a PIPE financing with a single healthcare-focused institutional investor, expected to provide $3.5 million in upfront gross proceeds at $5.91 per share, with potential additional proceeds of up to $17.5 million from milestone-based warrants. The company intends to use net proceeds to advance its lead asset into clinical trials. The offering is expected to close on June 29, 2026.

• · Purchase price per share: $5.91
• · Series A warrant exercise triggers: shareholder approval and filing of Clinical Trial Application in EEA for Phase 1 trial
• · Series B warrant exercise triggers: shareholder approval and MHRA approval for Phase 2a human challenge trial in UK
• · Series C warrant exercise triggers: shareholder approval and public announcement of positive Phase 2a data from UK trial
• · Registration rights agreement: file resale registration statement within 15 days after closing, use best efforts for effectiveness within 90 days (or 90 days after full review)
• · Placement agent: Curvature Securities LLC
• · Offering exempt from registration under Section 4(a)(2) and/or Regulation D

29-06-2026

U.S. GoldMining Inc. entered into a securities purchase agreement to sell 522,876 shares at $7.65 per share in a registered direct offering, expecting gross proceeds of $4.0 million. The offering is set to close on June 29, 2026, with net proceeds used for working capital and general corporate purposes.

• · The shares are offered under an effective shelf registration statement on Form S-3 (File No. 333-279435) filed on May 15, 2024, and declared effective on May 28, 2024.
• · The Purchase Agreement includes customary representations, warranties, and covenants, as well as indemnification for the Investor.
• · The legal opinion of Haynes and Boone, LLP regarding the validity of the shares is filed as Exhibit 5.1.

29-06-2026

Inhibikase Therapeutics, Inc. filed an 8-K on June 29, 2026, reporting amendments to its Certificate of Incorporation to limit personal liability of directors and officers to the fullest extent permitted by Delaware law, and to expand indemnification rights. The amendments were approved by stockholders at the annual meeting and became effective June 26, 2026. No financial figures were disclosed in this filing.

• · The amendment to Article IX of the Certificate of Incorporation eliminates personal liability of directors and officers for monetary damages for breach of fiduciary duty, to the fullest extent permitted by the DGCL.
• · The amendment also provides mandatory indemnification for directors and officers, and permissive indemnification for other employees and agents.
• · The amendment does not eliminate or reduce the effect of Article IX for matters occurring prior to the amendment.
• · The filing was made under Items 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers), 5.03 (Amendments to Articles of Incorporation or Bylaws), and 5.07 (Submission of Matters to a Vote of Security Holders).

29-06-2026

Volato Group, Inc. entered into a Securities Purchase Agreement on June 28, 2026, to sell 11,038,767 shares of Class A common stock at $0.165 per share in a registered direct offering, expecting gross proceeds of approximately $1.82M. The offering is subject to NYSE American approval. Additionally, director Alan Gaines resigned on June 24, 2026, to avoid potential conflicts as the company explores AI and digital infrastructure transactions.

• · The offering is a registered direct offering without a placement agent or underwriter, so no underwriting discounts or commissions are paid.
• · The company agreed to a 30-day lock-up on issuing additional shares or filing registration statements (except for employee benefit plans) and a 9-month restriction on Variable Rate Transactions.
• · The Purchase Agreement includes customary representations, warranties, and indemnification provisions.
• · The offering is made under an effective shelf registration statement on Form S-3 (File No. 333-290219) filed on September 12, 2025 and declared effective on September 30, 2025.
• · Alan Gaines resigned as director effective June 24, 2026, following the termination of the merger agreement with M2i Global, Inc. on June 4, 2026.
• · The company stated its intent to seek potential transactions in the AI and digital infrastructure sector after the merger termination.

29-06-2026

Picard Medical, Inc. appointed Dr. Joe Xiao to its Board of Directors on June 23, 2026, with a term expiring at the 2026 annual meeting. Dr. Xiao will also serve on the Audit, Compensation, and Nominating and Corporate Governance Committees. No material transactions or arrangements were disclosed in connection with his appointment.

• · Dr. Xiao was appointed to the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
• · Dr. Xiao entered into the Company's standard indemnification agreement for directors.
• · Compensation will follow the non-employee director policy described in the proxy statement filed June 15, 2026.
• · No arrangements or understandings exist between Dr. Xiao and any other person regarding his selection.
• · No transactions requiring disclosure under Item 404(a) of Regulation S-K were identified.

29-06-2026

Allegiant Travel Company announced early tender results for its 7.250% Senior Secured Notes due 2027, receiving valid tenders for $377,534,000 of the $403,009,000 outstanding principal amount (93.68% participation) by the Early Tender Deadline. The company also obtained consents from a majority of holders to eliminate most restrictive covenants and reduce the redemption notice period to 3 business days. However, the tender offer is contingent on the company successfully completing one or more debt financings, and any notes not purchased may be redeemed on August 15, 2026 at par.

• · The tender offer and consent solicitation were launched on June 9, 2026 via an Offer to Purchase and Consent Solicitation Statement.
• · The Proposed Amendments eliminate most restrictive covenants and certain events of default, and reduce the minimum redemption notice period from 30 days to 3 business days.
• · Holders who tender after the Early Tender Deadline but by the Expiration Time (July 9, 2026) will receive only the Tender Offer Consideration of $955 per $1,000 principal, not the Early Tender Premium.
• · The company may redeem any remaining notes on August 15, 2026 at 100% of principal plus accrued interest, but has no obligation to do so.
• · The tender is subject to the company successfully completing one or more debt financings.
• · Barclays Capital Inc. is acting as dealer-manager and solicitation agent.

29-06-2026

Art's-Way Manufacturing Co., Inc. entered into a $500,000 revolving credit facility with Bank Midwest on June 22, 2026, to fund deposits for a new fiberoptic laser and crane system for its Agricultural Products Segment. The facility is secondary to the company's existing $4,000,000 line of credit and will be converted to 15-year term debt upon equipment delivery, estimated in 16-18 weeks. The initial interest rate is 6.225% per annum, with a maturity date of March 30, 2027.

• · The Reserve Line of Credit matures on March 30, 2027.
• · The equipment delivery and installation is estimated in 16-18 weeks.
• · The term debt will have a 15-year term at an estimated rate of 6.50% per annum, which may fluctuate with market rates.
• · The Reserve Line of Credit is secondary to the existing $4,000,000 line of credit and will be utilized upon that line reaching capacity.

29-06-2026

Korn Ferry (KFY) announced a definitive agreement to acquire AMS from OMERS Private Equity for approximately £850 million (~$1.1 billion), combining cash (~£659M/$881M) and stock (~£191M/$255M). The deal is expected to close in Q2 FY'27 and be immediately accretive to EPS in the first full year, creating a global talent and organizational consulting leader with over 16,000 colleagues. However, the acquisition carries integration risks and requires regulatory clearances, and the purchase price relies on a specific exchange rate that may fluctuate.

• · AMS was founded by Rosaleen Blair in 1996.
• · AMS serves clients across financial services, technology, healthcare, life sciences, consumer, industrial, and public sector markets.
• · The combined firm will place a professional in a job approximately every 90 seconds.
• · Korn Ferry is the Official Talent & Organizational Consulting Partner of LA28.
• · The conference call for investors is scheduled for June 29 at 8:30 a.m. EDT.

29-06-2026

Theravance Biopharma has entered into a definitive agreement to be acquired by Zymeworks Inc. for $17.00 per share in cash, representing an equity value of approximately $929 million. Shareholders will also receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future monetization of ampreloxetine over ten years. The transaction, which follows a comprehensive strategic review, is expected to close in the second half of 2026 and represents a 22% premium to the company's closing price on March 3, 2026, and a 10% premium to its volume-weighted average price since that date.

• · The CVR entitles shareholders to 80% of net proceeds from any future license, divestiture or other monetization of ampreloxetine over the next ten years, with the remaining 20% to Zymeworks.
• · If a monetization transaction for ampreloxetine is not executed by closing, a designee from Theravance Biopharma will explore opportunities for 12 months post-closing.
• · The Strategic Review Committee was formed in 2024 and oversaw actions including the $225 million monetization of the TRELEGY royalty interest in 2025.
• · The transaction is subject to shareholder approval, regulatory approvals, and other customary closing conditions.
• · Advisors: Lazard (lead financial advisor), Evercore (financial advisor), Skadden (legal counsel) for Theravance; Kirkland & Ellis (legal), Matheson (tax counsel), TD Cowen (financial advisor on OMERS royalty note), MTS Health Partners (financial advice) for Zymeworks.

29-06-2026

Outdoor Holding Co (POWWP) dismissed its independent auditor WithumSmith+Brown, PC and engaged Grant Thornton LLP as its new independent registered public accounting firm, effective June 26, 2026. The change was approved by the Audit Committee and follows the filing of the company's annual report for the fiscal year ended March 31, 2026. No disagreements or reportable events occurred during the relevant periods, and the prior audit report was unqualified.

• · The dismissal and engagement were both approved by the Audit Committee on June 26, 2026.
• · Withum's audit report for the fiscal year ended March 31, 2026 was unqualified with no adverse opinion or disclaimer.
• · No disagreements or reportable events occurred during the fiscal year ended March 31, 2026 or the subsequent interim period through June 26, 2026.
• · Grant Thornton was engaged for the fiscal year ending March 31, 2027.
• · The company did not consult Grant Thornton on any accounting or auditing matters prior to engagement.

29-06-2026

Honeywell Technologies has completed the spin-off of its Aerospace Technologies business, which now operates as Honeywell Aerospace, effective June 29, 2026. This transaction, along with the previously separated Solstice Advanced Materials, completes Honeywell’s transformation into three independent, focused market leaders. Alongside the spin-off, Honeywell Technologies executed a 1-for-2 reverse stock split, reducing outstanding shares from approximately 634 million to about 317 million.

• · The spin-off distribution ratio was one share of Honeywell Aerospace common stock for every two shares of Honeywell Technologies common stock held as of the record date of June 15, 2026.
• · Honeywell Technologies common stock received a new CUSIP number (438516205) following the reverse split.
• · The number of authorized shares of Honeywell Technologies common stock was reduced from 2 billion to 1 billion concurrently with the reverse split.
• · Honeywell Technologies will file a supplemental 8-K later today presenting the Aerospace business as discontinued operations and providing recast quarterly financials for FY2024, FY2025, and Q1 2026.
• · No fractional shares were issued; cash will be provided in lieu of fractional shares for both the spin-off and reverse split.
• · Both the spin-off and reverse stock split were previously announced and completed simultaneously on June 29, 2026.
• · Honeywell Technologies will continue to trade under the ticker 'HON', while Honeywell Aerospace will trade under 'HONA'.

29-06-2026

Genesco Inc. (NYSE: GCO) announced the appointment of Jonathan Collins as Senior Vice President, Finance and Chief Financial Officer, effective August 3, 2026. Collins brings over 30 years of financial leadership experience, including senior roles at Walmart and most recently as CFO of America’s Car‑Mart. Mimi E. Vaughn, who had served as interim CFO since March 2026, will remain Board Chair, President and CEO. The appointment is part of Genesco’s continued execution of its ‘Footwear First’ strategy.

• · Effective date of CFO appointment is August 3, 2026.
• · Mimi E. Vaughn served as interim CFO since March 2026.
• · Collins spent 13 years at Walmart (2012‑2025) in senior finance roles across Africa, Flipkart (India) and Canada.
• · Most recently he was CFO of America’s Car‑Mart (2025‑2026).
• · Collins is a Certified Public Accountant and holds multiple advanced degrees from University of Illinois, Western Governors University and Kennesaw State University.
• · Genesco operates more than 1,200 retail stores along with branded e‑commerce websites.

29-06-2026

Rocket Lab (RKLB) will acquire Iridium (IRDM) for $54 per share in a cash-and-stock deal, implying an ~$8.0B enterprise value. The transaction combines Rocket Lab's launch and satellite manufacturing with Iridium's global L-band network and 2.55M+ subscribers, creating a vertically integrated space company. Iridium delivered $871.7M revenue and $495M OEBITDA (57% margin) in 2025, providing recurring cash flow; however, the deal is not expected to close until mid-2027 and remains subject to stockholder and regulatory approvals.

• · The cash component is $27.00 per share; the stock component is subject to an exchange ratio with a collar banded from $67.50 to $112.50.
• · Rocket Lab has received commitments for a $3.6B 364-day senior secured bridge term loan facility from Deutsche Bank and Wells Fargo.
• · Each Iridium director holding shares has entered into a voting agreement to support the transaction.
• · The transaction has been unanimously approved by the boards of both companies.
• · Iridium's 2025 OEBITDA margin was 57%.
• · Iridium supports more than 2.55 million active subscribers worldwide.

29-06-2026

Shoulder Innovations, Inc. (NYSE: SI) closed two new credit facilities totaling up to $50 million with Stifel Venture Banking, refinancing its existing debt with improved terms. The facilities include a $15 million fully funded term loan (interest-only through June 2029, maturing June 2031) and a $30 million undrawn line of credit with a $5 million accordion feature (maturing June 2029). The refinancing does not result in additional indebtedness or warrants, providing additional working capital capacity and financial flexibility.

• · Term loan interest rate: greater of prime rate minus 0.75% or 5.00%
• · Line of credit interest rate: greater of prime rate or 5.00%
• · Term loan is interest-only through June 30, 2029, and matures in June 2031
• · Line of credit matures in June 2029
• · No additional indebtedness or warrants at close
• · Company is a commercial-stage medtech firm focused on shoulder surgical care

29-06-2026

Honeywell Aerospace Inc. reported FY 2025 net sales of $17,404 million, up 13% from $15,445 million in FY 2024, with net income attributable to Honeywell Aerospace declining 4.6% to $2,687 million from $2,817 million. While full-year organic sales grew 12%, Q4 2025 net income fell sharply to $430 million from $571 million in Q4 2024, and the Engines & Power Systems segment posted a segment loss of $57 million in Q4 2025 due to a $373 million Flexjet-related litigation settlement.

• · FY 2025 total segment profit was $4,085 million, up from $3,708 million in FY 2024.
• · FY 2025 Adjusted EBIT was $4,458 million, up from $3,708 million in FY 2024.
• · Q4 2025 Engines & Power Systems segment profit was a loss of $57 million, compared to a loss of $129 million in Q4 2024.
• · FY 2025 Electronic Solutions segment profit was $1,988 million, up 4% from $1,912 million in FY 2024.
• · FY 2025 Control Systems segment profit was $1,523 million, up 24.2% from $1,226 million in FY 2024.
• · FY 2025 Engines & Power Systems segment profit was $691 million, essentially flat compared to $692 million in FY 2024.
• · FY 2025 organic sales growth was 12%, with Engines & Power Systems leading at 21%, Control Systems at 10%, and Electronic Solutions at 5%.
• · Q4 2025 organic sales growth was 20%, driven by Engines & Power Systems at 62% (partly due to the low base from the Bombardier adjustment in Q4 2024).
• · Environmental remediation expenses totaled $389 million in FY 2025, up from $235 million in FY 2024.
• · Transaction costs were $269 million in FY 2025, up from $0 in FY 2024.

29-06-2026

Zymeworks Inc. has entered into a definitive agreement to acquire Theravance Biopharma, Inc. for $17.00 per share, totaling approximately $929 million in cash consideration, adding YUPELRI® (revefenacin) to its portfolio. The acquisition is financed primarily through a $350 million non-recourse note from OMERS Life Sciences and Zymeworks' existing cash, with the transaction expected to close in the second half of 2026. While the deal is expected to be accretive to earnings and cash flow, generating ~$60 million annualized cash flow from YUPELRI® profit share, Zymeworks will contribute $219 million in cash at close and expects a $100 million milestone in Q1 2027 to offset outlay, with the company also continuing a share repurchase program for up to $125 million.

• · YUPELRI has been marketed in the U.S. since 2019 through a collaboration between Viatris and Theravance Biopharma.
• · Settlements reached with all YUPELRI generic filers for an April 2039 licensed launch date.
• · Theravance Biopharma eligible for $125M in commercial milestone payments from Viatris based on U.S. net sales.
• · Zymeworks will retain ~$2.5B in Irish tax attributes from Theravance Biopharma.
• · Zymeworks plans to complete Theravance Biopharma's organizational restructuring to reduce R&D and G&A costs.
• · Transaction expected to close in second half of 2026.
• · Zymeworks has repurchased 1,437,073 shares at an average price of $24.63 per share as of June 29, 2026.

29-06-2026

CIM Real Estate Finance Trust, Inc. (CMFT) acquired CIM Group, LLC's real assets management business and portfolio of investments, forming a combined company renamed CIM Group, Inc. The combined entity manages over $30 billion in assets and will operate as a diversified owner, operator, lender, developer and real assets management platform. CIM Group, LLC received 67.5% voting and economic ownership of the combined company, while existing CMFT shareholders hold the remaining 32.5%. The company will not be treated as a REIT for U.S. tax purposes and has committed to pursue a stock exchange listing within 24 months.

• · The transaction was unanimously approved by a Special Committee of CMFT's Board of Directors composed exclusively of independent directors, and by the full Board.
• · The combined company has committed to fund quarterly dividends over the next three years.
• · A majority-independent Board is expected, with existing CMFT Independent Directors continuing in their roles.
• · The combined company will continue regulatory reporting obligations, including annual, quarterly and periodic filings.
• · The combined company has committed to commence a process within 24 months to pursue a future listing of its common stock on a national stock exchange and to seek to complete such listing or an alternative liquidity event within five years.
• · Advisors: Goldman Sachs & Co. LLC (financial advisor) and Venable LLP (legal advisor) to the Special Committee; Taft Stettinius & Hollister LLP (legal advisor) to CMFT; Sullivan & Cromwell LLP (legal advisor) to CIM Group, LLC.

29-06-2026

BillionToOne, Inc. entered into a 12-year lease for 62,659 square feet of office and lab space at 3260 Whipple Road, Union City, CA, to expand oncology laboratory capacity by more than three times and increase total facility space by ~16%. The lease, commencing around August 1, 2027, carries aggregate base rent of approximately $46.7 million, a 12-month rent abatement, and a $12.5 million tenant improvement allowance. The expansion is driven by test volumes exceeding the company’s plan over the past year, but the lease adds a long-term financial obligation and the company remains subject to forward-looking risks.

• · Lease commencement is anticipated on or about August 1, 2027, after substantial completion of tenant improvements.
• · The lease includes an option to extend for an additional 10 years at the then-prevailing market rate.
• · The company will pay its pro rata share of operating expenses, taxes, and assessments related to the premises.
• · The laboratory space will be dedicated to oncology products, more than tripling the current oncology-dedicated lab space.
• · The lease was entered into on June 23, 2026, and the 8-K was filed on June 29, 2026.

29-06-2026

SafeSpace Global Corp (SSGC) announced the resignation of board member William Benjamin Pope, effective June 22, 2026. The resignation was not due to any disagreement with the company's operations, policies, or practices. No financial figures or performance metrics were disclosed in this filing.

• · The resignation was effective immediately on June 22, 2026.
• · The filing was signed by CEO Scott M. Boruff on June 29, 2026.
• · No replacement director was announced in this filing.

29-06-2026

Alpex Acquisition Corporation, a blank check company, announced the pricing of its $100 million initial public offering of 10,000,000 units at $10.00 per unit, with the units expected to trade on Nasdaq under 'ALPXU' starting June 25, 2026. The offering, managed by D. Boral Capital LLC, includes a 45-day over-allotment option for up to 1,500,000 additional units and is expected to close on June 26, 2026. As a SPAC, Alpex has not yet identified a target business combination, and the forward-looking statements highlight risks that the offering may not be completed as described.

• · The underwriters have a 45-day option to purchase up to 1,500,000 additional units to cover over-allotments.
• · Upon separate trading, Class A ordinary shares, warrants, and rights are expected to be listed under 'ALPX', 'ALPXW', and 'ALPXR' respectively.
• · The registration statement on Form S-1 (File No. 333-294978) was declared effective by the SEC on June 24, 2026.
• · Alpex is a blank check company with no target industry or geographic region limitation for its business combination search.

29-06-2026

Aimei Health Technology Co., Ltd. announced the resignation of director Julianne Huh effective June 24, 2026, for personal reasons with no disagreement with the company. The board appointed Daniel Veikko Polvi as a new director on June 29, 2026, citing his extensive experience in business management and strategic consulting. No financial metrics or performance data were disclosed in this filing.

• · Ms. Huh confirmed she has been paid all amounts due and released the company from all claims.
• · Mr. Polvi holds an MBA from BI Norwegian Business School (June 2018) and has been managing director of Shearwater Limited since May 2019.
• · No family relationships exist between Mr. Polvi and any director or executive officer, and no reportable transactions under Item 404(a) were identified.

29-06-2026

Cheetah Net Supply Chain Service Inc. (CTNT) and its sales agent AC Sunshine Securities LLC mutually terminated their Sales Agreement effective June 26, 2026, which had been in place since March 31, 2026. The termination eliminates the company's ability to issue and sell shares of Class A common stock through an at-the-market offering program under its existing S-3 registration statement. No amounts, fees, or expenses were due to the sales agent at termination, and no unsettled sales remain.

• · The Sales Agreement was originally dated March 31, 2026, meaning it was active for less than three months before termination.
• · The agreement related to the offer and sale of shares of Class A common stock, par value $0.0001 per share, under registration statement Form S-3 (File No. 333-281820).
• · Certain sections of the Sales Agreement survive termination, including Sections 7(g), 9, 10, 11(f), 16, and 17.
• · The termination was effective as of the close of business on June 26, 2026.

29-06-2026

FibroBiologics (FBLG) announced a private placement priced at-the-market under Nasdaq rules, with expected gross proceeds of $3.0 million upfront and potential additional proceeds of up to $6.0 million from the exercise of series A and series B warrants (each exercisable at $0.735 per share). The offering involves 4,081,633 shares (or pre-funded warrants) and corresponding warrants. However, there is no assurance any warrants will be exercised, and the company plans to use net proceeds for working capital and general corporate purposes, highlighting ongoing capital needs.

• · The series A warrants expire 5 years after the later of Stockholder Approval Date and effective date of the resale registration statement; series B warrants expire 18 months after the same trigger date.
• · The purchase price per share (and accompanying warrants) is $0.735.
• · The private placement is expected to close on June 29, 2026.
• · The offering is conducted under Section 4(a)(2) and/or Regulation D of the Securities Act; securities are unregistered and subject to a registration rights agreement.
• · The company has over 270 issued and pending U.S. and international patents.

29-06-2026

Synchrony Financial announced executive leadership changes to advance its digital growth, customer experience, and AI momentum. Carol Juel was named CEO of the Digital platform, succeeding Bart Schaller who is retiring after 35 years; Florin Arghirescu was promoted to CTO, and DJ Casto expanded his role to Chief People and Operations Officer. The changes reflect a strategic focus on digital-first partnerships, AI adoption, and operational excellence.

• · Synchrony is ranked #1 Best Company to Work For in the U.S. by Fortune and Great Place to Work.
• · The company serves tens of millions of consumers and supports hundreds of thousands of small and midsize businesses, including health and wellness providers.
• · Forward-looking statements are subject to risks detailed in the company's 10-K for the year ended December 31, 2025.

29-06-2026

Golub Capital Private Income Fund I entered into a second amended and restated side letter to its BANA Credit Facility on June 23, 2026, modifying the minimum utilization level for calculating the unused commitment fee through September 30, 2026. The amendment provides temporary relief on fee calculations, but no financial figures or performance metrics were disclosed in the filing.

• · The side letter was entered into on June 23, 2026, and filed on June 29, 2026.
• · The amendment modifies the minimum utilization level for unused commitment fee calculation through September 30, 2026.
• · The BANA Credit Facility was originally amended and restated on December 31, 2025.

29-06-2026

Golub Capital Private Income Fund S, through its subsidiary GPIF S Funding, entered into a second amended and restated side letter to its BANA Credit Facility on June 23, 2026. The amendment modifies the minimum utilization level for calculating the unused commitment fee through September 30, 2026. No financial figures or performance metrics were disclosed in this filing.

• · The side letter modifies the minimum utilization level for calculating the unused commitment fee through September 30, 2026.
• · The original credit agreement was amended and restated on December 31, 2025.

29-06-2026

Frontdoor, Inc. (FTDR) announced the expansion of its board to nine members and the election of Hilla Sferruzza, EVP and CFO of Meritage Homes (NYSE: MTH), as an independent director effective June 29, 2026. Sferruzza, a CPA with over 30 years of experience in public company finance, real estate, and accounting, will also serve on the Audit Committee. This appointment brings enhanced financial and real estate expertise to the board, with Sferruzza slated to stand for re-election at the 2027 annual meeting.

• · The board expanded to nine members unanimously.
• · Sferruzza is a Certified Public Accountant in Arizona and holds an Executive MBA from Washington State University and a BS in Business Administration from the University of Arizona.
• · She is a member of the Arizona State University W.P. Carey School of Business Dean’s Council and Finance Advisory Board.
• · Frontdoor handles approximately 3.8 million service requests annually for over 2.1 million members through a network of about 17,000 independent contractors.

29-06-2026

Immunic, Inc. held its 2026 annual meeting on June 29, 2026, where shareholders elected Michael Bonney, Thorvald Nagel, and Dr. Richard Rudick as Class III directors and approved an amendment to the 2019 Omnibus Equity Incentive Plan increasing authorized shares by 6,000,000 to a total of 8,644,887. The appointment of Baker Tilly as independent auditor for fiscal 2026 was also ratified. The company noted no emerging growth company status.

• · The Plan was originally adopted on June 14, 2019, and had previously been amended on June 28, 2023, March 4, 2024, and June 4, 2025.
• · The Company is a Delaware corporation with its common stock traded on Nasdaq under the symbol IMUX.
• · The Plan will expire on the earlier of the 10th anniversary of the Effective Date (June 14, 2019) or when all shares have been purchased or restrictions lapsed.

29-06-2026

Seaport Entertainment Group Inc. announced that Lucy Fato stepped down as EVP, General Counsel and Corporate Secretary effective June 25, 2026, and will serve as an Advisor to the CEO through August 24, 2026. Her separation is treated as a termination without cause under her employment agreement, with severance benefits contingent on her continued service through the separation date. No financial terms or replacement were disclosed.

• · Transition Date: June 25, 2026
• · Separation Date: August 24, 2026
• · Ms. Fato will serve as Advisor to the President and CEO during the transition period
• · Separation is classified as termination 'without cause' under her employment agreement
• · Severance payments and benefits are subject to release requirements and continued service through the Separation Date
• · The Transition Agreement is filed as Exhibit 10.1 to the 8-K

29-06-2026

Liquidmetal Technologies changed its independent auditor from BCRG Group to Simon & Edward LLP following BCRG's acquisition by S&E. The change was effective June 26, 2026, and there were no disagreements or reportable events in the prior periods. The audit reports for fiscal years 2024 and 2025 were unqualified.

• · Auditor change due to acquisition of BCRG by S&E, effective June 15, 2026.
• · No disagreements or reportable events during fiscal years 2024, 2025, and interim period through March 31, 2026.
• · Audit reports for 2024 and 2025 were unqualified.

29-06-2026

Fathom Holdings Inc. (FTHM) set compensation for two interim officers appointed June 16, 2026. Interim CEO Adam Rothstein receives $30,000 per month; Interim CFO Daniel Weinmann entered an employment agreement with a $300,000 annual base salary and a discretionary bonus target of up to 30% of base. Severance for Weinmann includes six months' base salary if terminated without cause or for good reason.

• · Rothstein's salary is $30,000 per month effective retroactively from June 16, 2026.
• · Weinmann's employment agreement includes a six-month severance of his then-current monthly base salary if terminated without cause or for good reason, subject to a release of claims.
• · No mention of Rothstein's bonus or severance terms.

29-06-2026

Datavault AI Inc. entered a binding term sheet with Scilex Holding Company on June 24, 2026, for the proposed sale of 837 BTC held in a digital wallet for a total purchase price of $50 million. Scilex will make an initial $30 million payment, with the remaining $20 million paid in quarterly installments through December 31, 2028, in cash or securities at Scilex's discretion. However, the transaction is subject to a definitive agreement and numerous conditions, and there is no assurance it will be consummated, posing significant execution risk.

• · Scilex has discretion to pay the purchase price in cash, its common stock, or publicly traded securities of its subsidiaries.
• · The term sheet may be terminated by either party, and failure to reach a definitive agreement could lead to costly litigation.
• · Remaining $20 million is payable in quarterly installments starting Q4 2026 and ending December 31, 2028.

29-06-2026

Pinnacle West Capital Corp. approved a $1.5 million discretionary credit award for Adam Heflin, EVP and Chief Nuclear Officer of its subsidiary Arizona Public Service Company, to be credited in installments from 2026 to 2029 and vesting on May 1, 2030. The award is subject to continued employment and forfeiture upon early separation, except in cases of death, disability, or termination without cause. No negative or flat performance metrics were reported in this filing.

• · The award is granted under Section 3.9 of the Deferred Compensation Plan of 2005 for Employees of Pinnacle West Capital Corporation and Affiliates.
• · The account vests on May 1, 2030, contingent on continued employment through that date.
• · Forfeiture of unvested credits occurs upon separation from service before vesting, except for death, disability, or termination without cause.
• · Amounts in the account accrue interest per the Plan's terms.

29-06-2026

Zimmer Biomet Holdings, Inc. entered into a Five-Year Revolving Credit Agreement dated June 26, 2026, with JPMorgan Chase Bank as administrative agent and a syndicate of lenders. The agreement provides for a $1.5 billion revolving credit facility for general corporate purposes and a $50 million letter of credit subfacility. The facility matures in five years and includes a financial condition covenant, incremental commitment provisions, and an extension option.

• · The credit agreement includes a financial condition covenant (Section 9.04) and a limitation on subsidiary indebtedness (Section 9.05).
• · The facility has an extension of maturity date provision (Section 2.05) and incremental commitment provisions (Section 5.05).
• · The agreement references a separate 364-Day Credit Agreement dated the same day.
• · The pricing grid is set forth in Annex I, and the initial commitments are listed in Schedule 2.01.

29-06-2026

Columbia Financial, Inc. announced the appointment of four Northfield Bancorp directors to its board, effective upon completion of the pending merger. The board size was increased from nine to thirteen directors. The appointees bring extensive banking, accounting, and legal expertise, but no committee assignments were made at this time.

• · The appointments are subject to and effective upon completion of the merger.
• · None of the Northfield Continuing Directors were appointed to any committees of the Company’s Board of Directors at the time of appointment.
• · Columbia Bank's board size was also increased from 11 to 15 directors, effective at the Bank Merger effective time.
• · Steven M. Klein is a licensed CPA with over 35 years of banking and financial reporting experience, including SEC reporting.
• · Paul V. Stahlin is designated as an audit committee financial expert under SEC rules for Northfield.
• · The Merger Agreement was entered into on January 31, 2026, and involves a second-step conversion of the MHC prior to the merger.

29-06-2026

Coyni, Inc. (formerly Logicquest Technology Inc.) disclosed the dismissal of its independent auditor, Simon & Edward LLP, and the engagement of CNGSN & Associates LLP as its new independent registered public accounting firm, effective April 7, 2026. The company reported no disagreements or reportable events with the former auditor during the fiscal years ended December 31, 2025 and 2024, and the subsequent interim period. This change in certifying accountant is a routine governance matter but may prompt investor attention to audit quality and financial reporting oversight.

• · The dismissal and engagement of the new auditor both occurred on April 7, 2026.
• · The engagement letter with CNGSN was dated March 27, 2026, prior to the formal ratification by the board.
• · No consultations with CNGSN occurred before engagement regarding accounting principles, audit opinions, or reportable events.
• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new financial accounting standards.

29-06-2026

Acura Pharmaceuticals, Inc. disclosed an amended loan schedule to a Secured Promissory Note dated November 10, 2022, with Abuse Deterrent Pharma, LLC. The aggregate principal has increased from $2,319,279 to $10,694,279 through 62 additional loans made between December 2022 and June 2026, with the most recent loan of $200,000 added on June 24, 2026. The filing indicates ongoing financial support from the lender, but also highlights Acura's continued reliance on debt financing.

• · The original promissory note was dated November 10, 2022, with an initial principal of $2,319,279.
• · Loans #1 through #50 (Dec 22, 2022 to Dec 31, 2025) added $7,075,000, bringing the aggregate to $9,394,279.
• · Subsequent loans #51 through #62 (Jan 2, 2026 to Jun 24, 2026) added $1,300,000, with the final loan of $200,000 on June 24, 2026.
• · The total increase in debt from the original note is $8,375,000 over approximately 3.5 years.

29-06-2026

Synergy CHC Corp. held its 2026 annual meeting on June 29, 2026, where stockholders approved all five proposals, including the election of five directors, ratification of RBSM as auditor, an amendment to the 2024 Equity Incentive Plan to increase authorized shares to 150,000,000 and permit repricing, approval of share issuance upon exercise of the Lender Warrant, and a reverse stock split up to 1-for-200. However, the company's outstanding shares are only 14,899,883, and the proposed 150,000,000 share pool represents a massive 10x dilution, while the reverse split authorization signals potential Nasdaq compliance concerns.

• · Proposal 3 (Plan amendment) received 6,782,598 votes for, 860,297 against, 8,451 abstentions, and 2,156,773 broker non-votes.
• · Proposal 4 (Lender Warrant share issuance) received 7,327,670 votes for, 301,715 against, 21,961 abstentions, and 2,156,772 broker non-votes.
• · Proposal 5 (Reverse stock split) received 8,827,762 votes for, 969,208 against, and 11,148 abstentions, with no broker non-votes.
• · All director nominees received between 7,176,292 and 7,184,954 votes for, with 466,393 to 475,055 votes withheld, and 2,156,772 broker non-votes each.
• · Proposal 2 (RBSM ratification) passed with 9,808,117 votes for, 472,432 against, and 13,197 abstentions.

29-06-2026

Freedom Holding Corp. (Nasdaq: FRHC) announced the appointment of Valeriy Kim as Chief Financial Officer, succeeding Evgeny Ler, who served as CFO since 2015 and will transition to a special advisor role focusing on financing and M&A. Mr. Kim, previously Vice President of Finance and CEO of a subsidiary, brings experience from his prior CFO role at Freedom Finance Global PLC (2020-2024). The filing contains no financial data or period-over-period comparisons.

• · Evgeny Ler had served as CFO since 2015.
• · Valeriy Kim, age 37, previously served as CFO of Freedom Finance Global PLC from 2020 to 2024.
• · Both Kim and Ler began their careers at Deloitte before joining Freedom Holding Corp.

29-06-2026

GCI Liberty, Inc. (GLIBK) entered into Amendment No. 1 to its Ninth Amended and Restated Credit Agreement on June 29, 2026, securing $480 million in new financing: $155 million in Incremental Term A-1 Loans, $300 million in Incremental Term A-2 Loans, and $25 million in Incremental Revolving Commitments. The proceeds will fund the Quintillion Acquisition (purchase of Q Gateway Intermediate Holdings, LLC) and refinance existing debt, including the retirement of a portion of the 2028 Notes. The amendment also adds a new issuing bank and updates legal opinions and compliance certificates.

• · The amendment was executed under Section 2.13 of the Existing Credit Agreement dated March 25, 2025.
• · The Incremental Revolving Commitments are solely for Letters of Credit and cannot be drawn as Revolving Loans (except for reimbursement obligations).
• · The Quintillion Acquisition is governed by a Securities Purchase Agreement dated April 21, 2026.
• · Conditions for effectiveness include delivery of legal opinions from O'Melveny & Myers LLP, Dillon Findley & Simonian, P.C., and Moira Smith, as well as a solvency certificate and compliance with anti-money laundering regulations.
• · The amendment adds new classes of Term Loans and Revolving Loans, separate from existing classes.

29-06-2026

Meritage Homes entered into a Twelfth Amendment to its Credit Agreement, increasing total commitments from $910M to $980M and extending the Class A Termination Date to June 24, 2031. The amendment also updates the minimum net worth test to $3,531,291,000 (down from $3,602,112,000) and adjusts certain interest rate definitions. No defaults were reported.

• · The amendment updates the Adjusted Daily Simple SOFR and Adjusted Term SOFR Rate definitions to include a 0.10% spread.
• · The L/C Commitment remains up to 100% of Total Commitment, with a specific Issuing Lender commitment of $370M as of June 24, 2026.
• · The amendment includes a reaffirmation of guarantees and no novation.

29-06-2026

CDT Equity Inc. dismissed its independent auditor, CBIZ CPAs P.C., and engaged Carr, Riggs & Ingram, L.L.C. (CRI) as new auditor, effective June 23, 2026. The previous audit report included a going-concern explanatory paragraph, and the company also disclosed material weaknesses in internal controls over financial reporting. This marks the second auditor change within 14 months, following the replacement of Marcum LLP in April 2025.

• · CBIZ CPAs' audit report for FY2025 contained a going-concern explanatory paragraph.
• · Material weaknesses identified: segregation of duties, lack of formal review process for transactions, inadequate internal control framework, failure to properly evaluate material transactions (leading to restatement), and inconsistent review of related-party transactions.
• · No disagreements or reportable events occurred during CBIZ CPAs' tenure beyond the disclosed material weaknesses.
• · The company did not consult CRI on accounting matters prior to engagement.
• · CBIZ CPAs provided a letter to the SEC dated June 29, 2026, agreeing with the company's statements.

29-06-2026

Kayne DL 2021, Inc. announced the resignation of director Albert Rabil III on June 29, 2026. Rabil stepped down immediately as an 'interested' director due to his employment with Kayne Anderson Capital Advisors. His departure was not due to any disagreement with the company, and the board is now composed entirely of four independent directors.

• · Albert Rabil III was a Class III director whose term would have expired at the 2029 annual meeting if not reelected.
• · Rabil did not serve on any Board committees at the time of his resignation.
• · The Board now consists solely of Independent Directors, with no 'interested' persons under the 1940 Act.

29-06-2026

Tenax Therapeutics adopted a Change in Control Plan and Severance Plan for eligible employees on June 26, 2026, while simultaneously amending the employment agreements of CEO Christopher Giordano, Thomas Staab, and Stuart Rich to provide them with severance and change-in-control benefits generally aligned with those plans. The amendments include enhanced severance terms, such as 12 months of base salary plus additional months based on tenure for non-CIC terminations, and 18 months of base salary for Mr. Giordano in connection with a change in control. The executive officers are excluded from the new plans and remain covered by their individual amended agreements.

• · The CIC Plan provides 'double trigger' equity acceleration and cash severance benefits to eligible employees upon a qualifying termination within three months before or 12 months after a Change in Control.
• · The Severance Plan provides cash severance benefits to eligible employees terminated without Cause, independent of a change in control, based on tenure and level.
• · Benefits under both plans are conditioned on the eligible employee's execution of a release of claims.
• · For non-CIC terminations, each executive receives 12 months of base salary plus an additional month per completed year of service (up to 12 additional months), a pro-rated annual bonus at 100% goal achievement, and 12 months of COBRA reimbursements.
• · For CIC-related terminations, Mr. Giordano receives 18 months of base salary and 18 months of COBRA reimbursements, while Mr. Staab and Dr. Rich receive 12 months of base salary and 12 months of COBRA reimbursements.
• · Dr. Rich receives accelerated vesting of all outstanding equity awards in both non-CIC and CIC termination scenarios.

29-06-2026

Hertz Global Holdings has entered into a Share Lending Agreement with J.P. Morgan Securities LLC, under which Hertz will lend 37,037,037 shares of its common stock to J.P. Morgan in connection with the issuance of $350 million (plus up to $50 million over-allotment) of 6.75% Exchangeable Senior First-Lien Secured PIK Notes due 2030 by The Hertz Corporation. The non-cash loan fee is a nominal $0.01 per share (totaling ~$370,370). The agreement includes standard collateral provisions and restricts J.P. Morgan from borrowing shares that would cause its beneficial ownership to exceed 7.5% of outstanding common stock.

• · The Facility Termination Date is the earliest of October 1, 2030, three months after no Exchangeable Notes remain outstanding, or termination under Section 15.
• · The loan is contingent upon the closing of the initial issuance of the Exchangeable Notes occurring substantially contemporaneously.
• · Borrower’s Section 16 Percentage is capped at 7.5% of outstanding Common Stock.
• · Collateral must have Market Value at least equal to the Market Value of the Loaned Shares on the Closing Date.
• · Eligible Non-Cash Collateral includes U.S. Treasury bills and notes, and irrevocable letters of credit from qualifying banks.

29-06-2026

Athene Holding Ltd. entered into two new revolving credit agreements on June 26, 2026: a $1.75 billion (expandable to $2.50 billion) facility with Citibank maturing in 2031, and a $2.60 billion (expandable to $3.10 billion) 364-day facility with Wells Fargo maturing in 2027. These agreements replace prior facilities and include financial covenants requiring minimum consolidated net worth of $22.06 billion (Citi) and $26.23 billion (Wells), with debt-to-capitalization capped at 40%.

• · The Citi Credit Agreement replaces a prior agreement dated June 30, 2023.
• · The Wells Credit Agreement replaces a prior 364-day agreement dated June 27, 2025.
• · Citi Credit Agreement interest margins range from 0.875% to 1.500% for Term SOFR and 0.000% to 0.500% for Base Rate, based on debt rating.
• · Wells Credit Agreement interest margins range from 1.000% to 1.250% for Term SOFR and 0.000% to 0.250% for Base Rate, based on financial strength rating.
• · Citi Credit Agreement undrawn commitment fee ranges from 0.070% to 0.175%.
• · Wells Credit Agreement undrawn commitment fee ranges from 0.080% to 0.125%.
• · Both agreements include customary covenants restricting liens, fundamental changes, affiliate transactions, and business changes.
• · The Citi Credit Agreement has a maturity of June 26, 2031, with two possible 1-year extensions.
• · The Wells Credit Agreement matures June 25, 2027, with possible 364-day extensions or term-out conversion.

29-06-2026

ITT Inc. announced the election of Bertrand Loy and Kevin Wheeler to its Board of Directors, effective August 1, 2026. Loy brings public company CEO experience and global manufacturing expertise, while Wheeler adds deep industrial leadership and M&A experience. The appointments reflect ITT's disciplined board refreshment strategy, with Loy joining the Audit Committee and Wheeler joining the Nominating and Governance Committee.

• · Bertrand Loy served as CEO of Entegris from 2012 to 2025 and became Executive Chairman in 2025.
• · Kevin Wheeler served as CEO of A. O. Smith from 2018 to 2025 and became Executive Chairman in 2025, with over 30 years at the company.
• · Loy holds an MBA from ESSEC Business School in France; Wheeler holds a BS in Finance from the University of Nevada and completed the Advanced Management Program at Harvard Business School.
• · Loy was appointed to the Audit Committee; Wheeler was appointed to the Nominating and Governance Committee.

29-06-2026

MediaAlpha entered into an agreement on June 25, 2026 to purchase Insignia's interest in its Tax Receivables Agreement (TRA) for $31.0 million in cash, a 55% discount to its estimated $68.7 million value. This reduces the company's total estimated TRA liability from $123.4 million to approximately $55.0 million as of June 30, 2026. The transaction was approved by disinterested directors and funded from subsidiary cash on hand and borrowing under its revolving credit facility.

• · The agreement is an Assignment, Assumption and Termination Agreement (the 'Agreement') entered into on June 25, 2026.
• · The purchase does not constitute a change of control or early termination under the TRA.
• · Remaining TRA payments will continue with respect to other counterparties.
• · To fund the payment, QLH made a pro rata distribution to its members, including certain directors and executive officers of the Company.
• · The Board approved the transaction, with a majority composed of independent and disinterested directors.

29-06-2026

United Therapeutics Corp held its 2026 Annual Meeting on June 26, 2026, where shareholders approved the 2026 Stock Incentive Plan, adding 1.5M new shares plus shares remaining from the prior plan (2,413,730) and shares subject to outstanding awards (4,941,655). All 12 director nominees were elected, and executive compensation was approved on an advisory basis. However, the 2026 Stock Incentive Plan received significant opposition with 10,070,290 votes against (28.0% of votes cast), indicating notable shareholder dissent.

• · Shareholder approval of executive compensation received 35,152,059 votes for and 1,048,505 against (2.9% against).
• · Ratification of Ernst & Young as auditor passed with 35,753,887 votes for and 1,647,415 against.
• · Director Kevin Tracey received the highest support with 36,187,554 votes for and only 18,239 against (0.05% against).
• · Director Christopher Causey received the lowest support with 32,342,983 votes for and 3,861,566 against (10.7% against).
• · Director Christopher Patusky also faced significant opposition with 32,649,292 votes for and 3,555,219 against (9.8% against).
• · The 2026 Plan replaces the Prior Plan; no further awards will be granted under the Prior Plan.